|Title of Invention||
"AN ANTINEOPLASTIC COMPOSITION".
|Abstract||This invention provides the use of a combination of CCI-779 and EKB-569 in the treatment of neoplasms. (FIG. 1)|
|Full Text||AN ANTINEOPLASTIC COMPOSITION
BACKGROUND OF THE INVENTION
This invention relates to the use of combinations of rapamycin 42-ester with
3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) and 4-dimethylamino-
but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-
Rapamycin is a macrocyclic triene antibiotic produced by Streptomyces
hygroscopicus, which was found to have antifungal activity, particularly against
Candida albicans, both in vitro and in vivo [C. Vezina et al., J. Antibiot. 28, 721
(1975); S.N. Sehgal et al., J. Antibiot. 28, 727 (1975); h. A. Baker et al., J. Antibiot
31, 539 (1978); U.S. Patent 3,929,992; and U.S. Patent 3,993,749]. Additionally,
rapamycin alone (U.S. Patent 4,885,171) or in combination with picibanil (U.S. Patent
4,401,653) has been shown to have antitumor activity.
The immunosuppressive effects of rapamycin have been disclosed in FASEB
3, 3411 (1989). Cyclosporin A and FK-506, other macrocyclic molecules, also have
been shown to be effective as immunosuppressive agents, therefore useful in
preventing transplant rejection [FASEB 3, 3411 (1989); FASEB 3, 5256 (1989);
R. Y. Calne et al., Lancet 1183 (1978); and U.S. Patent 5,100,899]. R. Martel et al.
[Can. J. Physiol. Pharmacol. 55, 48 (1977)] disclosed that rapamycin is effective in
the experimental allergic encephalomyelitis model, a model for multiple sclerosis; in
the adjuvant arthritis model, a model for rheumatoid arthritis; and effectively inhibited
the formation of IgE-like antibodies.
Rapamycin is also useful in preventing or treating systemic lupus
erythematosus [U.S. Patent 5,078,999], pulmonary inflammation [U.S. Patent
5,080,899], insulin dependent diabetes mellitus [U.S. Patent 5,321,009], skin
disorders, such as psoriasis [U.S. Patent 5,286,730], bowel disorders [U.S. Patent
5,286,731], smooth muscle cell proliferation and intimal thickening following vascular
injury [U.S. Patents 5,288,711 and 5,516,781], adult T-cell leukemia/lymphoma
[European Patent Application 525,960 A1], ocular inflammation [U.S. Patent
5,387,589], malignant carcinomas [U.S. Patent 5,206,018], cardiac inflammatory
disease [U.S. Patent 5,496,832], and anemia [U.S. Patent 5,561,138].
Rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid
(CCI-779) is ester of rapamycin which has demonstrated significant inhibitory effects
on tumor growth in both in vitro and in vivo models. The preparation and use of
hydroxyesters of rapamycin, including CCI-779, are disclosed in U.S. Patent
CCI-779 exhibits cytostatic, as opposed to cytotoxic properties, and may delay
the time to progression of tumors or time to tumor recurrence. CCI-779 is considered
to have a mechanism of action that is similar to that of sirolimus. CCI-779 binds to
and forms a complex with the cytoplasmic protein FKBP, which inhibits an enzyme,
mTOR (mammalian target of rapamycin, also known as FKBP12-rapamycin
associated protein [FRAP]). Inhibition of mTOR"s kinase activity inhibits a variety of
signal transduction pathways, including cytokine-stimulated cell proliferation,
translation of mRNAs for several key proteins that regulate the G1 phase of the cell
cycle, and IL-2-induced transcription, leading to inhibition of progression of the cell
cycle from g1 to S. The mechanism of action of CCI-779 that results in the G1 S
phase block is novel for an anticancer drug.
In vitro, CCI-779 has been shown to inhibit the growth of a number of
histologically diverse tumor cells. Central nervous system (CNS) cancer, leukemia (T-
cell), breast cancer, prostate cancer, and melanoma lines were among the most
sensitive to CCI-779. The compound arrested cells in the G1 phase of the cell cycle.
in vivo studies in nude mice have demonstrated that CCI-779 has activity
against human tumor xenografts of diverse histological types. Gliomas were
particularly sensitive to CCI-779 and the compound was active in an orthotopic glioma
model in nude mice. Growth factor (platelet-derived)-induced stimulation of a human
glioblastoma cell line in vitro was markedly suppressed by CCI-779. The growth of
several human pancreatic tumors in nude mice as well as one of two breast cancer
lines studied in vivo also was inhibited by CCI-779.
Protein tyrosine kinases are a class of enzymes that catalyze the transfer of a
phosphate group from ATP or GTP to tyrosine residue located on protein substrates.
Protein tyrosine kinases clearly play a role in normal cell growth. Many of the growth
factor receptor proteins function as tyrosine kinases and it is by this process that they
effect signaling. The interaction of growth factors with these receptors is a necessary
event in normal regulation of cell growth. However, under certain conditions, as a
result of either mutation or overexpression, these receptors can become deregulated;
the result of which is uncontrolled cell proliferation which can lead to tumor growth and
ultimately to the disease known as cancer [Wilks A.F., Adv. Cancer Res., 60, 43
(1993) and Parsons, J.T.; Parsons, S.J., Important Advances in Oncology, DeVita
V.T. Ed., J.B. Lippincott Co., Phila., 3 (1993) ]. Among the growth factor receptor
kinases and their proto-oncogenes that have been identified and which are targets of
the compounds of this invention are the epidermal growth factor receptor kinase
(EGF-R kinase, the protein product of the erbB oncogene), and the product produced
by the erbB-2 (also referred to as the neu or HER2) oncogene. Since the
phosphorylation event is a necessary signal for cell division to occur and since
overexpressed or mutated kinases have been associated with cancer, an inhibitor of
this event, a protein tyrosine kinase inhibitor, will have therapeutic value for the
treatment of cancer and other diseases characterized by uncontrolled or abnormal cell
growth. For example, overexpression of the receptor kinase product of the erbB-2
oncogene has been associated with human breast and ovarian cancers [Slamon, D.
J., et. al., Science, 244, 707 (1989) and Science, 235,1146 (1987)]. Deregulation of
EGF-R kinase has been associated with epidermoid tumors [Reiss, M., et. al., Cancer
Res., 51, 6254 (1991)], breast tumors [Macias, A., et al., Anticancer Res., 7, 459
(1987)], and tumors involving other major organs [Gullick, W.J., Brit. Med. Bull., 47,
87 (1991)]. Because of the importance of the role played by deregulated receptor
kinases in the pathogenesis of cancer, many recent studies have dealt with the
development of specific PTK inhibitors as potential anti-cancer therapeutic agents
[some recent reviews: Burke. T.R., Drugs Future, 17, 119 (1992) and Chang, C.J.;
Geahlen, R.L., J. Nat. Prod., 55,1529 (1992)].
4-Dirnethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-
7-ethoxy-quinolin-6-yl]-amide (EKB-569) is an EGFR kinase inhibitor which has
significant inhibitory effects on tumor growth in both in vitro and in vivo models. The
preparation and use of EGFR kinase inhibitors, such as EKB-569, are disclosed in
U.S. Patent 6,002,008.
BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS
FIG. 1 shows cytotoxicity curves of EKB-569, CCI-779, and combinations of
EKB-569 + CCI-779 in HCT116 cells.
FIG. 2 shows isobolograms (at the 50% effect level) of a EKB-569 + CCI-779
FIG. 3 shows isobolograms for EKB-569 + CCI-779 combinations derived from
different endpoints ranging from 50-65%.
FIG. 4 shows a 3-dimensional analysis of the synergistic interaction of a EKB-
569 + CCI-779 combination.
FIG. 5 shows a contour plot of the 3-dimensional synergy plot of a EKB-569 +
DESCRIPTION OF THE INVENTION
This invention provides the use of combinations of CCI-779 and EKB-569 as
antineoplastic combination chemotherapy. In particular, these combinations are
useful in the treatment of renal cancer, soft tissue cancer, breast cancer,
neuroendocrine tumor of the lung, cervical cancer, uterine cancer, head and neck
cancer, glioma, non-small lung cell cancer, prostate cancer, pancreatic cancer,
lymphoma, melanoma, small cell lung cancer, ovarian cancer, colon cancer,
esophageal cancer, gastric cancer, leukemia, colorectal cancer, and unknown primary
cancer. This invention also provides combinations of CCI-779 and EKB-569 for use
as antineoplastic combination chemotherapy, in which the dosage of either CCI-779
or EKB-569 or both are used in subtherapeutically effective dosages.
As used in accordance with this invention, the term "treatment" means treating
a mammal having a neoplastic disease by providing said mammal an effective amount
of a combination of CCI-779 and EKB-569 with the purpose of inhibiting growth of the
neoplasm in such mammal, eradication of the neoplasm, or palliation of the mammal.
As used in accordance with this invention, the term "providing," with respect to
providing the combination, means either directly administering the combination, or
administering a prodrug, derivative, or analog of one or both of the components of the
combination which will form an effective amount of the combination within the body.
The preparation of CCl-779 is described in U.S. Patent 5,362,718, which is
hereby incorporated by reference. An improved preparation of CCI-779 is disclosed in
US patent application SN 09/670,358, which is hereby incorporated by reference.
When CCI-779 is used as an antineoplastic agent, it is projected that initial i.v.
infusion dosages will be between about 0.1 and 100 mg/m2 when administered on a
daily dosage regimen (daily for 5 days, every 2-3 weeks), and between about 0.1 and
1000 mg/m2 when administered on a once weekly dosage regimen. Oral or
intravenous infusion are the preferred routes of administration, with intravenous being
EKB-569 can be prepared according to the procedures described in US Patent
6,002,008, which is incorporated by reference. Preferred procedures for the
preparation of EKB-569 are provided herein. When EKB-569 is used as an
antineoplastic agent it is projected that the initial oral dosage will be between 1 and
100 mg per day. Depending on patient tolerance, EKB-569 can be administered daily
for a treatment period, such as 14 days, followed by a rest period (no drug
administered), or can be administered on a continuous basis for a longer treatment
period (for example, 6 months or longer).
The antineoplastic activity of the CCI-779 plus EKB-569 combination was
confirmed in in vitro standard pharmacological test procedure; the following briefly
describes the procedure used and the results obtained.
Cell Proliferation Procedure - HCT 116 colon adenocarcinoma cells were
maintained in RPMl 1640 medium (Life Technologies, Inc., Gaithersburg, MD)
supplemented with 10% fetal bovine serum (FBS, Life Technologies) and 50 µg/ml
gentamlcin (Life Technologies) under 7% CO2 at 37°C. Cells were plated in 96-well
microtiter dishes (6000 cells/well) in 200 µl RPMl 1640 medium containing 5% FBS
and 50 µg/ml gentamicin and incubated overnight at 37°C. Compound dilutions were
prepared in the same medium, at 5X final concentration, and 50 µl of the drug dilution
was added to the cell-containing wells. For studies involving combinations of two
drugs, serial dilutions of one compound were prepared in the presence of a fixed dose
of a second compound. Alternatively, a checkerboard dilution series was employed.
Cells were cultured for three days in the presence of the drugs. Untreated cells were
included as controls. The percentage of surviving cells was determined using
sulforhodamine B (SRB, Sigma-Aldrich, St Louis, MO), a protein binding dye. Cellular
protein was precipitated in each well by the addition of 50 µl of 50% cold
trichloroacetic acid. After 1 hour, the plates were washed extensively in water and
dried. SRB dye reagent (0.4% SRB in 1% acetic acid, 80 µl per well) was added and
plates were kept at room temperature for ten minutes. Plates were then washed
thoroughly in 1% acetic acid and dried. Cell-associated dye was dissolved in 10 mM
Tris (150 µl) and the absorbance was read at 540 nm in a microtiter plate reader. The
concentration of compound that caused a fixed percentage inhibition of growth was
determined by plotting cell survival (relative to untreated cells) against the compound
Synergy Evaluation - Isobolograms were used to study the interaction of two
pharmacological agents. Here, the concentration of each drug alone which produces
a certain endpoint (e.g 50% inhibition of cell growth, IC50), is plotted on the two
graphical axes. The straight line connecting the two points represents equally
effective concentrations of all combinations of the two drugs if the interaction is purely
additive. A shift of the isobologram to the left of the predicted cytotoxicity (curve with
concave side up) represents a synergistic interaction. Conversely, a shift to the right
(isobologram with the convex side up) represents an antagonistic interaction. When
isobolograms for different endpoints were plotted on the same graph, the
concentration of each drug was expressed as the fraction of the concentration of each
drug alone that produced the same effect. This produces a symmetrical isobologram
with unit-less measures on each axis, and allows a direct comparison of different
A second model for studying drug interactions was proposed by Prichard and
Shipman [Antiviral Research. 14: 181-206 (1990)]. This is a 3-dimensional model:
one for each drug and the third for the biological effect. Theoretical additive
interactions are calculated from the individual dose-response curves, based on a
dissimilar sites model of additivity (Bliss independence). The calculated additive
surface, representing predicted cytotoxicity is subtracted from the experimental
surface to reveal areas of enhanced toxicity (synergy) or reduced toxicity
(antagonism). The resulting surface appears as a horizontal plane at 0% inhibition
above the calculated additive surface, if the interaction is additive. Peaks and valleys
deviating from this plane are indicative of synergy and antagonism, respectively.
MacSynergyll, a Microsoft Excel-based software was used to perform all calculations
automatically. This spreadsheet calculates the theoretical additive interactions, and
locates and quantifies synergistic or antagonistic interactions that are significant at the
95% confidence levels. The results were plotted as a 3-dimensional plot, or as a
Results - HCT 116 cells were chosen as they express low, but detectable
levels of EGFR, and are sensitive to inhibition by EGFR inhibitors. The cells are
somewhat resistant to CCI-779, but are inhibited by high doses (5-10 µg/ml) of this
drug. HCT-116 cells were cultured in the presence of EKB-569 alone, CCI-779 alone,
or a dilution series of EKB-569 with fixed doses of CCI-779. Following growth for 3
days, ceil survival was determined using the SRB test procedure. Cytotoxicity curves
are shown in Fig. 1. EKB-569 produced an IC50 value of 0.31 µg/ml in HCT116 cells.
When this compound was combined with 2.08 µg/ml CCI-779 (which caused 41%
inhibition of growth when administered alone), the IC50 value is reduced to 0.03 µg/ml,
a 10-fold decrease. When combined with 0.026 µg/ml CCI-779 (which alone inhibits
cell proliferation by 36 %), the IC50 value dropped to 0.051 µg/ml, a 6-fold decrease.
Similar results were observed when dose-response curves were produced with CCI-
779 in the presence of fixed doses of EKB-569. To identify the nature of this drug
interaction, isobolograms (at 50% effect level) of the combination of EKB-569 and
CCI-779 were generated (Fig. 2). The isobologram was deeply indented with the
concave side up, indicating a substantial synergistic interaction between the two
drugs. At the most synergistic point, 0.03 µg/ml of EKB-569 combined with 0.077
µg/ml CCI-779 was iso-effective with 0.31 µg/ml of EKB-569 alone or 4.3 µg/ml CCI-
779 alone (IC50 for each drug alone). Thus, a 10-fold reduction in the dose of EKB-
569 and a 50-fold reduction in the dose of CCI-779 was required to inhibit cell
proliferation by 50% when the drugs were combined, compared to either drug alone.
Isobolograms derived from different endpoints, ranging from 50 to 65% were also
examined. As shown in Fig 3., the isobolograms produced were almost
superimposable, indicating synergy at all effect levels tested.
The interaction between EKB-569 and CCI-779 was also evaluated using a 3-
dimensional analysis. Here, pharmacological interactions are presented in a 3-
dimensional plot with the plane at 0% representing additive interaction, and peaks and
valleys representing areas of synergy or antagonism, respectively, between the two
drugs. In Fig. 4, the combination of EKB-569 and CCI-779 resulted in a broad area of
synergistic interaction, consistent with the results shown in the isobologram studies.
A contour plot of the 3-dimensional synergy plot facilitates the identification of the
concentrations of drugs at which greatest synergistic toxicity occurs (Fig. 5). A broad
area of synergy was observed at 0.0005 to 3 µg/ml CCI-779 and 0.16 to 0.4 µg/ml
EKB-569. Within this area, two peaks of maximum synergy occurred at 0.0005 to
0.003 µg/ml and 0.05 to 0.3 µg/ml of CCI-779 and 0.25 to 0.37 µg/ml EKB-569.
Based on the results of these standard pharmacological test procedures,
combinations of CCI-779 plus EKB-569 acted synergistically together, and are useful
as antineoplastic therapy. More particularly, these combinations are useful in the
treatment of renal carcinoma, soft tissue sarcoma, breast cancer, neuroendocrine
tumor of the lung, cervical cancer, uterine cancer, head and neck cancer, glioma, non-
small cell lung cancer, prostate cancer, pancreatic cancer, lymphoma, melanoma,
small cell lung cancer, ovarian cancer, colon cancer, esophageal cancer, gastric
cancer, leukemia, colorectal cancer, and unknown primary cancer. As these
combinations contain at least two active antineoplastic agents, the use of such
combinations also provides for the use of combinations of each of the agents in which
one or both of the agents is used at subtherapeutically effective dosages, thereby
lessening toxicity associated with the individual chemotherapeutic agent.
In providing chemotherapy, multiple agents having different modalities of
action are typically used as part of a chemotherapy "cocktail." It is anticipated that the
combinations of this invention will be used as part of a chemotherapy cocktail that
may contain one or more additional antineoplastic agents depending on the nature of
the neoplasia to be treated. For example, this invention also covers the use of the
CCI-779/EKB-923 combination used in conjunction with other chemotherapeutic
agents, such as antimetabolites (i.e., 5-fluorouracil, floxuradine, thioguanine,
cytarabine, fludarabine, 6-mercaptopurine, methotrexate, gemcitabine, capecitabine,
pentostatin, trimetrexate, or cladribine); DNA crosslinking and alkylating agents (i.e.,
cisplatin, carboplatin, streptazoin, melphalan, chlorambucil, carmustine,
methclorethamine, lomustine, bisulfan, thiotepa, ifofamide, or cyclophosphamide);
hormonal agents (i.e., , tamoxifen, roloxifen, toremifene, anastrozole, or letrozole);
antibiotics (i.e., plicamycin, bleomycin, mitoxantrone, idaaibicin, dactinomycin,
mitomycin, doxorubicin or daunorubicin); immunomodulators (i.e., interferons, IL-2, or
BCG); antimitotic agents (i.e., estramustine, paclitaxel, docetaxel, vinblastine,
vincristine, or vinorelbine); topoisomerase inhibitors (i.e., topotecan, irinotecan,
etoposide, or teniposide.); and other agents (i.e., hydroxyurea, trastuzumab,
altretamine, retuximab, L-asparaginase, or gemtuzumab ozogamicin).
As used in this invention, the combination regimen can be given
simultaneously or can be given in a staggered regimen, with CCI-779 being given at a
different time during the course of chemotherapy than EKB-923. This time differential
may range from several minutes, hours, days, weeks, or longer between
administration of the two agents. Therefore, the term combination does not
necessarily mean administered at the same time or as a unitary dose, but that each of
the components are administered during a desired treatment period. The agents may
also be administered by different routes. For example, in the combination of CCI-779
plus EKB-569, it is anticipated that the CCI-779 will be administered orally or
parenterally, with parenterally being preferred, while the EKB-569 may be
administered parenterally, orally, or by other acceptable means. These combination
can be administered daily, weekly, or even once monthly. As typical for
chemotherapeutic regimens, a course of chemotherapy may be repeated several
weeks later, and may follow the same timeframe for administration of the two agents,
or may be modified based on patient response.
As typical with chemotherapy, dosage regimens are closely monitored by the
treating physician, based on numerous factors including the severity of the disease,
response to the disease, any treatment related toxicities, age, health of the patient,
and other concomitant disorders or treatments.
Based on the results obtained with the CCI-779 plus EKB-569 combinations, it
is projected that the initial i.v. infusion dosage of CCI-779 will be between about 0.1
and 100 mg/m2, with between about 2.5 and 70 mg/m2 being preferred. It is also
preferred that the CCl-779 be administered by i.v., typically over a 30 minute period,
and administered about once per week. The initial daily dosages of EKB-569 will be
between about 1 and 100 mg, with between 5 and 75 mg being preferred. After one
or more treatment cycles, the dosages can be adjusted upwards or downwards
depending on the results obtained and the side effects observed.
Oral formulations containing the active compounds of this invention may
comprise any conventionally used oral forms, including tablets, capsules, buccal
forms, troches, lozenges and oral liquids, suspensions or solutions. Capsules may
contain mixtures of the active compound(s) with inert fillers and/or diluents such as
the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars,
artificial sweetening agents, powdered celluloses, such as crystalline and
microcrystalline celluloses, flours, gelatins, gums, etc. Useful tablet formulations may
be made by conventional compression, wet granulation or dry granulation methods
and utilize pharmaceutically acceptable diluents, binding agents, lubricants,
disintegrants, surface modifying agents (including surfactants), suspending or
stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc,
sodium lauryl sulfate, microcrystalline cellulose, carboxymethylcellulose calcium,
polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum, sodium citrate,
complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium
phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry
starches and powdered sugar. Preferred surface modifying agents include nonionic
and anionic surface modifying agents. Representative examples of surface modifying
agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium
stearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal
silicon dioxide, phosphates, sodium dodecylsulfate, magnesium aluminum silicate,
and triethanolamine. Oral formulations herein may utilize standard delay or time
release formulations to alter the absorption of the active compound(s). The oral
formulation may also consist of administering the active ingredient in water or a fruit
juice, containing appropriate solubilizers or emulsifiers as needed.
In some cases it may be desirable to administer the compounds directly to the
airways in the form of an aerosol.
The compounds may also be administered parenterally or intraperitoneally.
Solutions or suspensions of these active compounds as a free base or
pharmacologically acceptable salt can be prepared in water suitably mixed with a
surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in
glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary
conditions of storage and use, these preparation contain a preservative to prevent the
growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous
solutions or dispersions and sterile powders for the extemporaneous preparation of
sterile injectable solutions or dispersions. In all cases, the form must be sterile and
must be fluid to the extent that easy syringability exists. It must be stable under the
conditions of manufacture and storage and must be preserved against the
contaminating action of microorganisms such as bacteria and fungi. The carrier can
be a solvent or dispersion medium containing, for example, water, ethanol, polyol
(e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures
thereof, and vegetable oils.
For the purposes of this disclosure, transdermal administrations are
understood to include all administrations across the surface of the body and the inner
linings of bodily passages including epithelial and mucosal tissues. Such
administrations may be carried out using the present compounds, or pharmaceutically
acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions,
and suppositories (rectal and vaginal).
Transdermal administration may be accomplished through the use of a
transdermal patch containing the active compound and a carrier that is inert to the
active compound, is non toxic to the skin, and allows delivery of the agent for systemic
absorption into the blood stream via the skin. The carrier may take any number of
forms such as creams and ointments, pastes, gels, and occlusive devices. The
creams and ointments may be viscous liquid or semisolid emulsions of either the oil-
in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in
petroleum or hydrophilic petroleum containing the active ingredient may also be
suitable. A variety of occlusive devices may be used to release the active ingredient
into the blood stream such as a semi-permeable membrane covering a reservoir
containing the active ingredient with or without a carrier, or a matrix containing the
active ingredient. Other occlusive devices are known in the literature.
Suppository formulations may be made from traditional materials, including
cocoa butter, with or without the addition of waxes to alter the suppository"s melting
point, and glycerin. Water soluble suppository bases, such as polyethylene glycols of
various molecular weights, may also be used.
The following provides the preparation of EKB-569 from commercially
available starting materials or starting materials that can be made according to
available literature procedures.
211 ml dimethylamine (2M in THF, 0.422 moles) was added drop-wise to a solution of
50 g TMS-4-bromocrotonate (0.211 moles, 75.9% by GC-MS) in 250 ml of THF at 0-
50°C under N2. The reaction mixture was stirred at room temperature for 30 minutes.
A white solid by-product was filtered off. 2 ml water was added to the filtrate followed
by seeding. The crystals formed were filtered and washed with ether to give 18.3 g
(from two crops) off -white solid product. Yield was 67.2% (98% purity by GC-MS,
NMR was consistent with the structure).
120 ml dimethylamine (2M in THF, 0.24 moles) was added drop-wise to a solution of
20 g methyl 4-bromocrotonate (85% purity, 0.095 moles) in 150 ml of THF at 0-50°C
under N2. The reaction mixture was stirred for 15 minutes at room temperature. TLC
(9:1 CH2CI2: MeOH with few drops of Et3N) showed residual methyl 4-bromo-
crotonate. The reaction mixture was heated to 40-450C for 15 minutes. A white solid
by-product was filtered off. The filtrate was evaporated to give a yellow oil (14 g). The
yellow oil was dissolved in 100 ml CH2CI2 and washed with H2O twice. The aqueous
layer was back extracted with 100 ml CH2CI2. The CH2CI2 layers were combined,
dried over MgSO4 and filtered. The filtrate was evaporated to give an oil (12 g). Yield
was 88%. NMR indicated desired product with trace methyl 4- bromocrotonate.
Preparation of Methyl 4-N,N-dimethylamlnocrotonate hydrochloride on large
A 3L flask was charged with tetrahydrofuran (0.71 kg, 0.80 L). Methyl 4-
bromocrotonate (0.20 kg, 0.13 L, d = 1.522 g/mL) was added and rinsed with
tetrahydrofuran (0.18 kg, 0.20 L). The solution was stirred and cooled to 0-10°C. An
additional funnel was charged with a solution of dimethylamine in tetrahydrofuran and
added over (1 h 15 min) keeping the temperature at 0-10°C. The mixture was stirred
for a minimum of 30 mins and checked for reaction completion by TLC. The reaction
was complete when there is = 2% detectable starting material (methyl 4-bromo-
crotonate) present. The mixture was filtered cold on a Buchner funnel into a 3 L multi-
neck flask, rinsed with pre-chilled (0-10°C) tetrahydrofuran (2 x 0.18 kg, 2 x 0.20 L),
and suction maintained until dripping stops. The flask was equipped with an agitator,
thermometer, and a setup for vacuum distillation. The solution was concentrated by
distillation under a reduced pressure of (125-200 mm Hg) and at a maximum pot
temperature of (40°C) to a pot volume of (200 mL). Isopropanol (0.22 kg, 0.28 L) was
added and the mixture cooled to 0-10°C. The distillation stillhead was replaced with
an addition funnel charged with a solution of HCI in isopropanol, which was added
over 45 min until pH of 2.0-3.0 was reached, while maintaining a temperature 0-10°C.
The mixture was held for a minimum 30 min, and fileted cold on a Buchner funnel,
rinsed with isopropanol (2 x 0.12 kg, 2 x 0.15 L). The filter cake was dammed and
suction maintained until dripping stopped. The product was dried in a vacuum oven at
50°C and 10 mm Hg for 18-20 h.
Preparation of 4-dimethylaminocrotonic acid hydrochloride from methyl
A NaOH solution (3.35 g in 25 ml H2O, 0.084 moles) was added drop-wise to a
solution of 12 g methyl 4-dimethylaminocrotonate (0.084 moles) in 100 ml MeOH at
room temperature. The reaction mixture was heated to 40-45ºC for 1 hour then cooled
to room temperature. The pH was adjusted to 1-2 with 5 N HCI. The mixture was
concentrated to a thick oil which was triturated with dehydrated alcohol to form a solid.
The solid by-product was filtered off. The filtrate was evaporated to an oil which was
triturated with IPA. Seven (7.0) g of white solid product was obtained. Yield was 50%
with the purity 86.3 % by GC-MS.
Preparation of 4-N,N-dimethylaminocrotonic acid hydrochloride on large scale
A 2 L multi-neck flask was equipped with agitator, thermometer, addition funnel, and.
nitrogen protection. The flask was charged with ethanol (0.39 kg, 0.50 L). Methyl 4-
N,N-dimethylamino crotonate hydrochloride (0.125 kg) was added and rinsed with
ethanol (0.10 kg, 0.125 L). The suspension was stirred and cooled to 0-10°C. The
addition funnel was charged with sodium hydroxide (50%) (0.11 kg, 0.072 L, d=1.53
g/mL) and addd over 20 min keeping the temperature at 0-10°C. A slight exotherm
was observed and the mixture turned yellow. The mixture was stirred for a minimum
of 15 min, and then warmed to 18-22°C, and held for a minimum of 4 h. The reaction
was checked for completion by TLC . The reaction is complete when there is = 2%
detectable starting material (methyl 4-N,N-dimethylaminocrotonate hydrochloride)
present The mixture was cooled to 0-10°C. An addition funnel was charged with a
solution of HCI in isopropanol and added over 40 min until pH 2.0-3.0 was attained,
while maintaining the pot temperature of 0-10°C. The mixture was sturred for a
minimum of 30 min, and filtered cold on a Buchner funnel into a 2 L multi-neck flask,
rinsed with cold ethanol (0-10°C) (2 x 0.05 kg, 2 x 0.063 L) with suction maintained
until dripping stops. The flask was equpped with an agitator, thermometer, and setup
for vacuum distillation. Solvent was removed under a reduced pressure of 50-100
mm Hg and at a maximum pot temperature of (40°C) to a pot volume of 160-180 mL.
Isopropanol (0.049 kg, 0.063 L) was added, and the mixture warmed to 35-40°C over
10 min. Acetone (0.10 kg, 0.13 L) was added over 20 min while maintaining the pot
temperature at 35-40°C. The mixture was seeded and cooled to ambient temperature
20-25°C, and held there for a minimum of 12-18 h. The mixture was cooled to
0-10°C, held there for a minimum of 1 h. A mixture of isopropanol (0.049 kg, 0.063 L)
and acetone (0.10 kg, 0.13 L) was prepared, stirred to homogenize, and cooled to
0-10°C. The mixture was filtered cold on a Buchner funnel, rinsed with isopropanol/
acetone (2 x 0.074 kg, 2 x 0.096 L), and the filter caked dammed while maintaining
suction until dripping stopped. The product was dried in a vacuum oven at 50°C and
10 mm Hg for 18-20 h.
Preparation of 4-dimethylamInocrotonyt anilide from 4-dimethylaminocrotonic
Thionyl chloride (0.36 ml, 0.005 moles) was added drop-wise to a solution of 0.33 g 4-
dimethylaminocrotonic acid hydrochloride (0.002 moles) in 15 ml CH2CI2 containing 2
drops of DMF at 0°C under N2. The reaction mixture was refluxed for 30 min. Then
0.72 ml aniline (0.008 moles) was added drop-wise to the reaction mixture at 0°C and
stirred for 1 hour at room temperature. A solid by-product was filtered. The filtrate was
evaporated to give an oil (0.6 g). GC-MS data shows that the oil is 11.7% 4-
dimethylaminocrotonic acid hydrochloride and 85% of desired product.
Preparation and isolation of 4-N,N-dimethylamlnocrotonoylchlorlde
A well stirred suspension 4-dimethylaminocrotonic acid hydrochloride (5.0 g, 30 mmol)
in cold (0°C) THF (40 mL) and DMF (2 pipet drops) was treated with oxalyl chloride
(3.15 mL, 36 mmol). The mixture was stirred at 20-25 °C for 3 h then cooled to 0°C
and held for 30 min. The solids were collected on Buchner funnel (under a blanket of
nitrogen) and washed with cold (0°C) THF (3x5 mL). The product was dried under
vacuum (- 1 torr) at 40-50°C for 3 h to give 4.0 g of 4-dimethylaminocrotonoyl
chloride hydrochloride. This material is characterized as its methyl ester by treatment
of the solid with methanol.
Alternatively, the title compound can be prepared in CH3CN and used directly for the
Preparation of EKB-569
A 3 L multi-neck flask was equipped with an agitator, thermometer, dip tube, and
nitrogen protection. The flask was charged with N-methyl pyrrolidinone (0.77 kg, 0.75
L, d=1.033 g/mL). At ambient temperature, 4-[3-chloro-4-fluorophenyl]amino-6-
amino-3-cyanc-7-ethoxy quinoline (0.0748 kg) [see, US Patent 6,002,008] was added
and the mixture stirred while heating to 40-45 °C and hold for 15 min. The flask was
cooled to 0-10°C. The mixture containing 4-N,N-dimethylaminocrotonoyl chloride
hydrochloride was transferred via dip tube and positive nitrogen pressure to the 3 L
flask over 30-45 min, while maintaining 0-10°C. The mixture was kept at 0-10°C for a
minimum of 2 h. The reaction was checked for completion by HPLC. The reaction is
complete when there is = 2% of the starting material (4-[3-chloro-4-fluorophenyl]-
amino-6-amino-3-cyano-7-ethoxy quinoline) present. A 12 L multi-neck flask
equipped with agitator, thermometer, dip tube, and nitrogen protection was charged
with water (2.61 kg, 2.61 L). Sodium bicarbonate (0.209 kg) was added and stirred
until a solution was obtained. The solution was cooled to 20-24°C. The NMP-CH3CN
mixture was transferred, via dip tube and positive nitrogen pressure, to the 12 L flask
over 45-60 min, while maintaining 20-24°C. The mixture was maintained at 20-24°C
for a minimum of 1 h, and filtered on a Buchner funnel, and rinsed with water (3 x 0.40
kg, 3 x 0.40 L) with suction being maintained until dripping stops. The product was
dried in a vacuum oven at 50°C and 10 mm Hg for 28-30 h to give 78.5 g (86% yield)
1. An antineoplastic composition which comprises an antineoplastic
effective amount such as herein described of a combination of CCI-779 and EKB-669.
2. A pharmaceutical composition comprising CCl-779 and EKB-569
capable of being used in the preparation of a medicament for the treatment of
neoplasm in a mammal.
3. A composition as claimed in claim 1 or 2 in which CCI-779 is provided
in a subtherapeutically effective amount such as herein described.
4. A composition as claimed fn claim 1 or 2 in which EKB-569,is provided
in a subtherapeutically effective amount such as herein described.
5. A composition as claimed in claim 1 or 2 in which both CCI-779 and
EKB-569 are provided in subtherapeutically effective amounts such as herein
6. A composition as claimed in any one of claims 1 to 5 in which the
neoplasm is one of the following: renal cancer, soft tissue sarcoma, breast cancer,
neuroendocrine tumor of the lung, cervical cancer, uterine cancer, a head and neck
cancer, glioma, non-small cell lung cancer, prostate cancer, pancreatic cancer,
lymphoma, melanoma, small cell king cancer, ovarian cancer, colon cancer,
esophageai cancer, gastric cancer, leukemia, colorectal cancer or unknown primary
7. A product comprising CCI-779 and EKB-569 as a combined preparation
for simultaneous, separate or sequential use in the treatment of a neoplasm in a
8. A product as claimed in claim 7 in which the neoplasm is one of the
following: renal cancer, soft tissue sarcoma, breast cancer, neuroendocrine tumor of
the lung, cervical cancer, uterine cancer, a head and neck cancer, glioma, non-small
cell lung cancer, prostate cancer, pancreatic cancer, lymphoma, melanoma, small cell
lung cancer, ovarian cancer, colon cancer, esophageal cancer, gastric, cancer,
leukemia, colorectal cancer or unknown primary cancer.
This invention provides an antineoplastic composition which comprises
rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-
779) and 4-dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-
cyano-7-ethoxy-quinolin-6-yl]-amide (EKB-569). The invention also provides a
product comprising CCI-779 and EKB-569 as a combined preparation for
simultaneous, separate or sequential use in the treatment of a neoplasm in a
mammal. In the composition or product of the invention either CCI-779 or EKB-569
or both may be used in subtherapeutically effective amounts.
|Indian Patent Application Number||00097/KOLNP/2004|
|PG Journal Number||09/2008|
|Date of Filing||28-Jan-2004|
|Name of Patentee||WYETH|
|Applicant Address||FIVE GIRALD FARMS MADISON, NJ 07940-0874 USA.|
|PCT International Classification Number||A61K31/395|
|PCT International Application Number||PCT/US02/24841|
|PCT International Filing date||2002-08-06|